The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Loan | Alive

Total Raised


Last Raised

$250K | 2 yrs ago

About Mosaic Biosciences

Mosaic Biosciences is advancing a fundamentally new class of synthetic materials to support native tissue regeneration. With its proprietary platform technology, Mosaic expects to significantly impact the field of tissue regeneration.

Mosaic Biosciences Headquarter Location

3415 Colorado Avenue

Boulder, Colorado, 80309,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Mosaic Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Mosaic Biosciences is included in 2 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Mosaic Biosciences Patents

Mosaic Biosciences has filed 7 patents.

The 3 most popular patent topics include:

  • Biomaterials
  • Biotechnology
  • Molecular biology
patents chart

Application Date

Grant Date


Related Topics




Biomaterials, Blood tests, Blood, Clusters of differentiation, Cell biology


Application Date


Grant Date



Related Topics

Biomaterials, Blood tests, Blood, Clusters of differentiation, Cell biology



Latest Mosaic Biosciences News

Ingenia Therapeutics & Mosaic Biosciences Present Preclinical Data on the Variants of the Bispecific Antibody IGT-427 for the Treatment of Degenerative Retinal Diseases

May 2, 2022

IGT-427 is a bispecific antibody that potently blocks VEGF and activates Tie-2. Variants of IGT-427 had long intravitreal half-lives, suggesting the potential for a less frequently administered and highly efficacious treatment for diabetic macular edema and wet age-related macular degeneration. & BOULDER, Colo.--( BUSINESS WIRE )--Ingenia Therapeutics and Mosaic Biosciences today announced the presentation of new data on pharmacokinetically-enhanced variants of IGT-427, Ingenia’s bispecific antibody that potently blocks VEGF and activates Tie-2. IGT-427, being optimized and developed for the treatment of diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD), was described, yesterday, at the 2022 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), being held in Denver, Colorado from May 1 – 5, 2022. The poster, entitled: “Variants of IGT-427 are long-acting, bispecific antibodies for the treatment of degenerative retinal diseases,” was presented by Eric Furfine, Ph.D., Mosaic’s Chief Executive and Scientific Officer (CESO). The data demonstrated IGT-427’s potential for a superior efficacy profile and improved convenience over standard of care VEGF blocking agents or combination VEGF- and Ang-2-blocking agents. A copy of the presentation materials can be accessed on the Events and Presentations section of the Ingenia and Mosaic websites. Key highlights include: IGT-427 potently binds and blocks VEGF signaling and activates Tie-2 more effectively than Ang-2 blockade PEGylation increased IGT-427’s ocular half-life from approximately 4 days to 8 days with minimal effects on activity “VEGF blockade is a revolutionary treatment for DME and wet AMD, on average preserving vision for many years compared to prior therapies. The combination of Ang-2 inhibition with VEGF inhibition adds another powerful tool to the treatment arsenal. Nonetheless, the frequency of intraocular administration and the substantial portion of inadequately responding patients continues to drive the need for new therapies. IGT-427’s ability to activate Tie-2 signaling more strongly and durably over Ang-2 inhibition has the potential to make variants of IGT-427 be a best-in-class therapy,” said Sangyeul Han, CEO of Ingenia. “The ocular pharmacokinetic enhancement engineered into IGT-427 by Mosaic scientists provides the potential for reduced frequency of administration compared to the standard of care and emerging therapeutics. In combination with its superior target engagement property, a long-lasting IGT-427 variant can be a more effective and durable option in multiple retinal disease markets,” added Eric Furfine, Ph.D., CESO at Mosaic. In September 2020, Ingenia and Mosaic entered into a strategic collaboration to further optimize Ingenia’s protein therapeutics for improved drug properties, including intraocular delivery. Ingenia retains global commercial rights for all collaboration products. About Ingenia Therapeutics Ingenia’s proprietary microvasculature protection technology is expected to provide a method for recovering and protecting small blood vessels from various microvascular destabilizing insults, such as VEGF, pro-inflammatory cytokines, and high levels of blood glucose. The technology has anti-inflammatory, anti-leakage, and anti-angiogenic properties and provides a novel alternative to established VEGF blockers, which act in a VEGF-dependent manner. Ingenia’s products utilizing the technology will allow for improved outcomes by modulating both VEGF-dependent and VEGF independent pathological pathways. For more information, please visit . About Mosaic Biosciences Mosaic Biosciences is a private biotechnology company providing full-service protein and antibody therapeutic discovery and engineering capabilities for a range of partners, including venture capital, small start-up companies, small molecule companies, or development companies looking to engage in drug discovery. For more information, please visit . Contacts

Mosaic Biosciences Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Mosaic Biosciences Rank

  • When was Mosaic Biosciences founded?

    Mosaic Biosciences was founded in 2009.

  • Where is Mosaic Biosciences's headquarters?

    Mosaic Biosciences's headquarters is located at 3415 Colorado Avenue, Boulder.

  • What is Mosaic Biosciences's latest funding round?

    Mosaic Biosciences's latest funding round is Loan.

  • How much did Mosaic Biosciences raise?

    Mosaic Biosciences raised a total of $3.55M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.